Study on the Enhancement of Intestinal and Immune Functions Through Probiotic Intervention
Launched by WECARE PROBIOTICS CO., LTD. · Mar 3, 2025
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at whether a specific type of probiotic, called Bifidobacterium longum subsp. infantis BI45, can help improve gut health and boost the immune system in healthy adults. Participants will take this probiotic daily for a period of time and will also provide some health samples, like blood and stool, during their visits to the clinic. The trial is not yet recruiting participants, but they are looking for healthy adults aged between 65 and 74 years who can commit to attending three follow-up visits.
To be eligible, participants need to be willing to take the probiotic or a placebo (a dummy pill) each day and be able to hear, read, and understand instructions. However, people with certain health conditions, such as serious digestive diseases, neurological disorders, or those who have recently undergone major medical procedures, cannot participate. This trial aims to gather information on the safety and effectiveness of the probiotic, helping researchers understand its potential benefits for gut and immune health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Willing to undergo 3 follow-up visits during the intervention period Be willing to provide blood, urine and stool samples 2 times during the intervention period
- • 2. Willing to self-administer probiotic or placebo once a day during the intervention period
- • 3. Good eyesight, can read and write, can wear glasses
- • 4. Have good hearing and be able to hear and understand all instructions during the intervention
- Exclusion Criteria:
- • 1. Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)
- • 2. Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor, prolonged coma - not including general anaesthesia)
- • 3. Have received/are receiving treatment for the following mental disorders: alcohol/drug/substance abuse dependence, schizophrenia, psychosis, bipolar disorder
- • 4. Take medication for depression or low mood Internal organ failure (heart, liver or kidney failure, etc.)
- • 5. Have received radiation or chemotherapy in the past
- • 6. Have undergone a general anesthesia procedure/procedure within the past three years, or plan to undergo a general anesthesia procedure/procedure within the next 3 months during this trial period
- • 7. Have had hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past
About Wecare Probiotics Co., Ltd.
wecare probiotics co., ltd. is a leading biotechnology firm dedicated to advancing gut health through innovative probiotic solutions. With a robust portfolio of research and development initiatives, the company focuses on formulating high-quality probiotic products that are backed by scientific evidence. Committed to enhancing the well-being of individuals, wecare probiotics collaborates with healthcare professionals and academic institutions to conduct clinical trials that evaluate the efficacy and safety of its formulations. The company's mission is to empower consumers with effective, research-driven probiotic options, fostering a healthier future for all.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, Henan, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported